Anastasia Floros
Family Medicine · Carleton, MINPI 1275948432
Payments from drug & device makers
Across 234 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$549
- AbbVie$514
- Lilly USA, LLC$507
- Pfizer$390
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$253
- AstraZeneca$245
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,026100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,026 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 118 | $107,296 |
| TrulicityDulaglutide | 82 | $88,160 |
| MounjaroTirzepatide | 63 | $80,357 |
| FarxigaDapagliflozin Propanediol | 91 | $68,442 |
| EliquisApixaban | 46 | $42,960 |
| OzempicSemaglutide | 41 | $40,630 |
| JanuviaSitagliptin Phosphate | 43 | $32,679 |
| XareltoRivaroxaban | 25 | $32,550 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $28,210 |
| Victoza 3-PakLiraglutide | 11 | $11,604 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,791 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 73 | $5,725 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 288 | $5,586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 129 | $5,420 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $507 | $168,517145 claims |
| Boehringer IngelheimJardiance | $46 | $107,296118 claims |
| AstraZenecaFarxiga | $245 | $68,44291 claims |
| PfizerEliquis | $390 | $42,96046 claims |
| Novo NordiskOzempic | $549 | $40,63041 claims |
| GSKTrelegy Ellipta | $43 | $28,21036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Carleton
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.